StreetAlpha.app
Home › Stocks › PRCT

PROCEPT BioRobotics Corp (PRCT)

$23.78
▲ +1.02%
LAST CLOSE · NOV 17

PROCEPT BioRobotics makes robotic systems that use imaging and a waterjet to remove prostate tissue, mainly for hospitals. It last closed at $23.78 on Nov 17, up 1.02% on the day. The average 12-month price target from 4 analysts is $24.25 (+2.0% from the last close), with a high of $30.00 and a low of $21.00. Analyst consensus is Hold, based on the latest ratings from 4 firms (1 buy, 3 hold, 0 sell).

AI Auto Pilots
Is PRCT in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$352.3M
+17.5% vs a year ago
Net income
−$114.9M
−32.6% margin
EPS (diluted)
−$2.02
Free cash flow
−$85.1M
−24.1% margin
Valuation
Market cap
$1.4B
57.5M shares
P/E
–
No P/E while losing money
Price to sales
3.9
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$218.4M
At Sep 30
Debt
$51.8M
At Sep 30
Shareholder equity
$328.9M
Shares outstanding
57.5M
At Oct 29
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $34.5M$34.5MFY2021FY2022: $75.0M$75.0MFY2022FY2023: $136.2M$136.2MFY2023FY2024: $224.5M$224.5MFY2024FY2025: $308.1M$308.1MFY2025

From PRCT's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 4). Last 12 months adds up the four latest quarters.

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Hold
Based on 4 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Hold
4firms
1 Buy3 Hold0 Sell
Each firm's latest rating on PRCT in the past 90 days
Average 12-month target
$24.25
▲ 2.0% upside

Based on 4 analysts who set a price target on PRCT in the past 90 days. The average target is $24.25, with a high of $30.00 and a low of $21.00, compared with the last close of $23.78.

Low $21.00Avg $24.25High $30.00
Blue marker: last close $23.78
Highest target$30.00
Average target$24.25
Lowest target$21.00
Latest rating changes
Truist SecuritiesTarget lowered
Nov 6Hold$25 → $24
UBSMaintained
Nov 6Hold$21
Leerink PartnersTarget lowered
Nov 5Hold$29 → $22
BarclaysInitiated
Oct 7Buy$30
TD CowenMaintained
Aug 5Buy$28
DateFirmActionRatingPrice target
Nov 6Truist SecuritiesTarget loweredHold$25 → $24
Nov 6UBSMaintainedHold$21
Nov 5Leerink PartnersTarget loweredHold$29 → $22
Oct 7BarclaysInitiatedBuy$30
Aug 5TD CowenMaintainedBuy$28
Loading…

Technical Analysis

PRCT · as of the Nov 17 close · updated after every close
Bounce inside a longer downtrend, nearing overbought

The stock is 11% above its 20 day and 18% above its 50 day average. It is 4% above its 200 day average, so the longer trend is still up. Momentum is strong (RSI 68), near overbought. The nearest support is the Pivot at $23.66, and the nearest resistance the swing high (Nov 5) at $24.07.

Short trendBullish
Long trendBearish
MomentumStrong
StretchNear overbought
VolatilityHigh, 5.4%/day
Key levels
$38.1152 week high+60.3%
$24.23Pivot R1+1.9%
$24.07Swing high (Nov 5)+1.2%
$23.78Last close
$23.66Pivot−0.5%
$23.22Pivot S1−2.4%
$22.85200 day average−3.9%
$21.1620 day average−11.0%
$20.69Swing low (Aug 20)−13.0%
$19.97100 day average−16.0%
$19.5850 day average−17.7%
$16.6752 week low−29.9%
Indicators
RSI (14)67.89Strong, overbought above 70Neutral
MACD1.25Above its signal lineBullish
Stochastic88.9Near the top of its rangeOverbought
ADX (14)40.3Strong uptrend
Williams %R-9.7Oversold below −80, overbought above −20Overbought
CCI (20)107.6Oversold below −100, overbought above 100Overbought
Rate of change+17.9%Change over 10 sessionsBullish
ATR (14)$1.29Typical daily range, 5.4% of price
MA 10Above
MA 20Above
MA 50Above
MA 100Above
MA 200Above
What happened before, for PRCT

What happened before

See how PRCT did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow PRCT usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How PRCT has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in PRCT in the last 90 days.

Loading…

See today’s whale options flow across the market →

PRCT Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ●108 buying vs 123 selling
  • ▼Held by funds -0.7 pts
  • ▼Funds holding -25
  • ▲Superinvestors: 2 added, 0 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding232257−9.7%
In funds' top 1000–
Held by funds94.8%95.4%−0.7 pts
New / increased26 / 8236 / 109−25.5%
Reduced / sold out72 / 5165 / 37+20.6%
Put/call ratio1.940.48+299.8%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See PRCT institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether PRCT is in one of them and how their past PRCT trades turned out.

PRCT in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered PRCT in an article yet. Here's the latest on the wider market.

About PROCEPT BioRobotics

PROCEPT BioRobotics makes surgical robots used to treat benign prostatic hyperplasia, a common condition in which the prostate gland enlarges and is not cancerous. Its AquaBeam and HYDROS robotic systems use a disposable handpiece, real time imaging and a waterjet that removes prostate tissue without heat. The company sells mainly to hospitals in the United States, with some sales through distribution partners, ambulatory surgery centers and leasing companies, and it sells to customers in other countries through its sales team and distribution partners. It is based in San Jose, California.

Headquarters
San Jose, CA